Item 1.01 Entry into a Material Definitive Agreement.

On June 30, 2009, Symbollon Pharmaceuticals, Inc. signed a distribution agreement with Integra Labs, Inc. granting Integra the exclusive right to distribute Symbollon's dietary supplement, IoGen™, in countries allowing over-the-counter sales of the product. Under the agreement, Integra will assume all manufacturing, sales and marketing responsibilities for the product. Integra will purchase Symbollon's existing inventory of IoGen at cost. Integra shall pay Symbollon a royalty on all sales of IoGen. The initial term of the agreement is for five years, subject to the achievement of certain milestones and minimum sales requirements. Pursuant to the agreement, the parties intend to identify other OTC product opportunities for Symbollon's iodine technology which would be distributed by Integra.

Item 3.02 Unregistered Sales of Equity Securities.

On June 29, 2009, Symbollon's Board of Directors granted Mr. Desjourdy, its Chief Executive Officer, Chief Financial Officer and President, 10,000,000 shares of restricted Class A common stock. The shares will vest one-half each of the next two anniversaries of the grant date, subject to his continued service as an officer and director of Symbollon.

On June 29, 2009, Symbollon issued 1,000,000 shares of Class A common stock to Kelly Black for services rendered.

The securities were issued pursuant to the exemption afforded by Section 4(2) of the Securities Act of 1933. The securities issued will not be or have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.